Next 10 |
home / stock / nvo / nvo articles
Thursday, Germany’s competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH&n...
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says t...
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 27.13% on an annualized basis producing an average annual return of 39...
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evid...
Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA) shares are volatile Thursday. The company announced the acquisition of AgBiome’s platform assets ...
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock h...
Novo Nordisk A/S (NYSE:NVO) has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic (semaglutide) will n...
Costco Wholesale Corporation (NASDAQ:COST) has launched a weight management program to help its members in their weight loss journey. The program w...
AstraZeneca Plc’s (NASDAQ:AZN) Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a s...
News, Short Squeeze, Breakout and More Instantly...
Novo Nordisk A/S Company Name:
NVO Stock Symbol:
NYSE Market:
Thursday, Germany’s competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH&n...
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says t...
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 27.13% on an annualized basis producing an average annual return of 39...